Revisiting malignant hypertension: rationale and design of the ‘HAMA cohort’, on behalf of the ESH working group ‘hypertension and the kidney’
Romain Boulestreau(Inserm), Philippe Gosse(Inserm), Michel Pâques(Centre Ophtalmologique d'Imagerie et de Laser), Pantelis Sarafidis(Ippokrateio General Hospital of Thessaloniki), Alexandre Persu(Cliniques Universitaires Saint-Luc), Stéphane Debeugny, Benjamin Maïer(Université Paris Cité), Sébastien Rubin(Université de Bordeaux), Mikaël Mazighi(Inserm), Hervé Dréau, Jean‐Michel Halimi(Centre Hospitalier Universitaire de Tours), Sophie Bonnin(Fondation de Rothschild), Antoine Crémer(Hôpital Saint-André), Pierre‐Louis Tharaux(Inserm), Aurélien Lorthioir(Assistance Publique – Hôpitaux de Paris)
Cited by 6
Related Papers
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
|Science|2020|3.2k
Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia
|JAMA Internal Medicine|2020|777
A transient ischaemic attack clinic with round-the-clock access (SOS-TIA): feasibility and effects
|The Lancet Neurology|2007|671
Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths
|Science Immunology|2021|638
European Stroke Organisation (ESO) - European Society for Minimally Invasive Neurological Therapy (ESMINT) Guidelines on Mechanical Thrombectomy in Acute Ischemic Stroke
|Journal of NeuroInterventional Surgery|2019|570